Method for treatment of diarrhea-predominant irritable bowel syndrome
View Patent ↗The present invention provides methods for treating diarrhea-predominant irritable bowel syndrome comprising administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea-predominant irritable bowel syndrome (d-IBS). Treatment of d-IBS includes the treatment of the diarrhea component of d-IBS as well as the pain, abdominal discomfort and other symptoms associated with d-IBS. In one embodiment, the inhibitor of chloride-ion transport is crofelemer.
1. A method of treating a patient having pain associated with diarrhea-predominant irritable bowel syndrome (d-IBS), comprising administering to the patient a composition comprising a proanthocyanidin polymer derived from C. lechleri in an amount bioequivalent to crofelemer at a dosage of about 100 mg per day to about 300 mg per day.
2. The method of claim 1 , wherein the proanthocyanidin polymer is crofelemer.
3. The method of claim 1 , wherein the composition is orally administered.
4. The method of claim 3 , wherein the proanthocyanidin polymer is crofelemer.
5. The method of claim 4 , wherein crofelemer is enteric coated.
6. The method of claim 5 , wherein crofelemer is administered to the patient at about 250 mg per day.
7. The method of claim 5 , wherein crofelemer is administered to the patient at about 125 mg twice daily.
8. The method of claim 1 , wherein the amount of the proanthocyanidin polymer is bioequivalent to crofelemer at a dosage of about 250 mg per day.
9. The method of claim 1 , wherein the amount of the proanthocyanidin polymer is bioequivalent to crofelemer at a dosage of about 125 mg twice daily.
10. The method of claim 1 , wherein the number of pain-free days are increased by at least 10% after administration of the composition.
11. The method of claim 1 , wherein the average level of pain as measured by a pain score is decreased after administration of the composition.
12. The method of claim 1 , wherein the number of days free of the urgency for stool passage is increased after administration of the composition, wherein said urgency is associated with d-IBS.
13. The method of claim 1 , wherein the patient is a human female.
14. The method of claim 1 , wherein the composition is administered twice daily.
15. A method of treating a patient having urgency for stool passage associated with diarrhea-predominant irritable bowel syndrome (d-IBS), comprising orally administering to the patient a composition comprising enterically coated crofelemer in an amount effective to reduce urgency for stool passage associated with d-IBS, wherein crofelemer is administered to the patient at about 200 mg per day to about 300 mg per day.
16. The method of claim 15 , wherein the daily stool frequency is also decreased after administration of the composition.
17. The method of claim 15 , wherein the crofelemer is administered to the patient at about 125 mg twice a day.
18. The method of claim 15 , wherein the composition is administered twice daily.